Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).
Li, Susan; Ozguroglu, Mustafa; Luna, Yesenia; Mundle, Suneel; Chi, Kim N.; Fizazi, Karim; Namphuong Tran, Namphuong Tran; Fein, Luis Enrique; Matsubara, Nobuaki; Antolin, Alfredo Rodriguez; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; Sulur, Giri